Ricerca Biosciences competitors

James E. Brown, D.V.M. co-founded DURECT in February 1998 and has served as President, Chief Executive Officer and a Director since June 1998. He previously worked at ALZA Corporation as Vice President of Biopharmaceutical and Implant Research and Development from June 1995 to June 1998. Prior to that, Dr. Brown held various positions at Syntex Corporation, a pharmaceutical company, including Director of Business Development from May 1994 to May 1995, Director of Joint Ventures for Discovery Research from April 1992 to May 1995, and held a number of positions including Program Director for Syntex Research and Development from October 1985 to March 1992. Dr. Brown holds a B.A. from San Jose State University and a D.V.M. (Doctor of Veterinary Medicine) from the University of California, Davis where he also conducted post-graduate work in pharmacology and toxicology.

President, Chief Executive Officer and Director of SCYNEXIS Inc. (Nasdaq: SCYX) and Director of various public companies and non-profit organizationsCompleted several successful rounds of financing and company restructuringExperience as a Director in Boards of public companies (Audit Committee, Compensation Committee and Governance & Nominating Committee) Managed groups up to 1,600 employees in global organizations and R&D budgets up to $950MM/yearOver 35 products approved through various regulatory paths [505(b)1, 505(b)2, 510(k) devices and ANDA] in the US and globally in Europe and South America:Anti-Infectives: Cedax (ceftibuten, Global), Isepacin (isepamicina - Europe), Cleeravue-M (minocycline for skin infections - US), Teflaro (ceftaroline - US), Colobreathe (Inhaled Colistin for cystic fibrosis - Europe), Avycaz (Ceftazidime/Avibactam)Oncology: Intro-A (Interferon-α in Non-Hodgkin lymphoma - US), Fareston (toremifene for breast cancer -US), Temodar (Temozolomide for brain tumors- Global) Central Nervous System: Subutex (buprenorphine for opioid addictions, Global), Savella (milnacipran for fibromyalgia - US), Lexapro pediatric (escitalopram - US), Namenda XR (memantine for Alzheimer disease, US), Fetzima (levomilnacipran for Major Depression Disorder - Global) Cardiovascular: Bystolic (nebivolol for hypertension - US)Gastroenterology: Linzess (linaclotide for IBSc and CIC - US)Respiratory Medicine: Daliresp (roflumilast for COPD - US), Tudorza (Aclidinium for COPD - US)Dermatology: Lotrisone Lotion (US for eczema), Mometasone Pediatric (US), MimyX (US), Duac (Global), Ciclopirox Shampoo (Global), Ciclopirox solution (Global), Rosac Wash (US), Brevoxyl Pads (US), Levulan (Global)Generics (US): Griseofulvin Suspension, Sodium Sulfacetamide Wash, Urea CreamOTC/Cosmeceuticals: Physiogel sunscreen (International), PanOxyl 10%, Foaming Acne Wash, Clariderm (International), Mimyx (US), SunMAX line (International), LactiCare HC (International)

Stephan Kutzer is a Chief Executive Officer at CAMBRIDGE MAJOR LABORATORIES and Chief Executive Officer at AAIPharma Services. He has worked as COO:Pharma & Biotech Mkt Segment at Lonza America Inc., Head:Performance Chemicals at Lonza America Inc., and Assistant Production Manager at Lonza America Inc.. Stephan attended Technical University of Munich.

John Ratliff served as Chief Executive Officer of Covance Drug Development, the world’s most comprehensive drug development company. He is a highly respected biopharmaceutical leader, with extensive experience in increasingly influential roles in the industry. In 2018, Ratliff was appointed Chairman for the Association of Clinical Research Organizations. Previously John was president and CEO of HUYA Bioscience International. His healthcare industry experience also includes almost 10 years at Quintiles, the world’s largest provider of product development and integrated healthcare services, where he served as Chief Financial Officer before becoming President and Chief Operating Officer. He was a member of the Quintiles board of directors. Prior roles throughout his career included CFO at Acterna, a provider of communications test solutions for telecommunications and cable network operators, and positions of increasing responsibility during his 19-year tenure at IBM.

Mr. Patel’s lifelong drive and constant desire to discover what’s next has carried Amneal Pharmaceuticals from humble beginnings to an emerging global presence. Patel is the recipient of several industry honors including the 2011 Ernst & Young National Entrepreneur of the Year Life Sciences Award® and supports various philanthropic and charitable causes both in the US and abroad. Patel and his wife, Priti Patel, established the Niswarth Children Foundation in 2013, with the goal of bringing fresh water, sanitation, sustenance, and education to one million underprivileged children. Patel received his bachelor’s degree in commerce from H.A. College of Commerce, India, and his Bachelor of Science in business administration from New Jersey City University. He also received an honorary degree of doctor of humane letters from New Jersey City University in recognition of his efforts to serve others and help them transform their lives. Patel serves on the boards of the Generic Pharmaceutical Association, the Art of Living Foundation, the New Jersey City University Foundation, and the Family Reach Foundation.

Aaron Greenblatt is a Chief Executive Officer at G&W Laboratories Inc. He has worked as Director: Business Dev & Sales at G&W Laboratories Inc, Director:Supply Chain at G&W Laboratories Inc, and Chief Commercial Officer at G&W Laboratories Inc. Aaron studied at University of Maryland.

David Seltzer is a Chairman/Pres/CEO/Treasurer at HI TECH PHARMACAL CO INC, Board Member at NovelStem International Corp, and Owner at Leading Pharma. He has experience at Bergen Brunswig Corp and AMERISOURCEBERGEN CORP and has worked as Exec VP:Admin/Treasurer/Secy at HI TECH PHARMACAL CO INC, Treasurer/Secretary at HI TECH PHARMACAL CO INC, and VP:Admin/COO/Treasurer/Secy at HI TECH PHARMACAL CO INC. David attended Queens University of Charlotte.